ANGO Stock Looks Promising on New Ischemia Study for Auryon System

Company Overview - AngioDynamics, Inc. (ANGO) has initiated a clinical study named AMBITION BTK to compare the Auryon Atherectomy System combined with standard balloon angioplasty against standard balloon angioplasty alone for treating infrapopliteal lesions in patients with critical limb ischemia below-the-knee [1] - The Auryon Atherectomy System is an advanced laser-based technology designed to treat arterial blockages while minimizing damage to vessel walls, and it is FDA-cleared for treating blockages and in-stent restenosis in the lower limbs [9][10] Clinical Study Details - The AMBITION BTK trial aims to recruit up to 200 participants across 30 hospital-based sites, with a companion registry including up to 1,500 patients treated with the Auryon system who do not qualify for the RCT [5] - This trial builds on the success of a previous study that demonstrated the safety and effectiveness of the Auryon system in treating complex BTK lesions, where 60 patients were treated with excellent clinical results and minimal complications [6][8] Financial Performance - AngioDynamics reported an adjusted loss per share of 4 cents for the second quarter of fiscal 2025, an improvement from a loss of 5 cents in the same quarter the previous year [12] - The company's net sales for the second quarter of fiscal 2025 were $73.0 million, reflecting a 9.2$31.5 million, driven by strong performances from the Auryon system and other products [13] Market Position and Growth Potential - AngioDynamics has a market capitalization of $504.2 million and a P/S ratio of 1.76, which is lower than the industry average of 2.83 [4] - The development of the Auryon system is expected to enhance AngioDynamics' position in the growing market for peripheral artery disease treatments, potentially leading to increased sales and market share [3] - The global laser atherectomy devices market is projected to grow from$182.1 million in 2022 to over $345.4 million by 2031, with a CAGR of 7.4%, driven by the rising prevalence of atherosclerosis and demand for minimally invasive procedures [11]